These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 12124177)
21. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. Li S; Couvillon AD; Brasher BB; Van Etten RA EMBO J; 2001 Dec; 20(23):6793-804. PubMed ID: 11726515 [TBL] [Abstract][Full Text] [Related]
22. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Okuda K; Golub TR; Gilliland DG; Griffin JD Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688 [TBL] [Abstract][Full Text] [Related]
23. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Liang X; Hajivandi M; Veach D; Wisniewski D; Clarkson B; Resh MD; Pope RM Proteomics; 2006 Aug; 6(16):4554-64. PubMed ID: 16858728 [TBL] [Abstract][Full Text] [Related]
24. Mechanisms of transformation by the BCR/ABL oncogene. Sattler M; Griffin JD Int J Hematol; 2001 Apr; 73(3):278-91. PubMed ID: 11345193 [TBL] [Abstract][Full Text] [Related]
25. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Ramaraj P; Singh H; Niu N; Chu S; Holtz M; Yee JK; Bhatia R Cancer Res; 2004 Aug; 64(15):5322-31. PubMed ID: 15289338 [TBL] [Abstract][Full Text] [Related]
26. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239 [TBL] [Abstract][Full Text] [Related]
27. Targeting BCR tyrosine177 site with novel SH2-DED causes selective leukemia cell death in vitro and in vivo. Peng Z; Yuan Y; Li YJ; Wang HX; Shi J; Cao WX; Luo HW; Deng JR; Feng WL Int J Biochem Cell Biol; 2012 Jun; 44(6):861-8. PubMed ID: 22349215 [TBL] [Abstract][Full Text] [Related]
28. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052 [TBL] [Abstract][Full Text] [Related]
29. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. MacPartlin M; Smith AM; Druker BJ; Honigberg LA; Deininger MW Leukemia; 2008 Jul; 22(7):1354-60. PubMed ID: 18548107 [TBL] [Abstract][Full Text] [Related]
30. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597 [TBL] [Abstract][Full Text] [Related]
31. Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. LaMontagne KR; Flint AJ; Franza BR; Pandergast AM; Tonks NK Mol Cell Biol; 1998 May; 18(5):2965-75. PubMed ID: 9566916 [TBL] [Abstract][Full Text] [Related]
32. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Gishizky ML; Cortez D; Pendergast AM Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904 [TBL] [Abstract][Full Text] [Related]
33. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921 [TBL] [Abstract][Full Text] [Related]
34. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226 [TBL] [Abstract][Full Text] [Related]
35. The SH2-containing adapter protein GRB10 interacts with BCR-ABL. Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873 [TBL] [Abstract][Full Text] [Related]
36. BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. Traina F; Carvalheira JB; Saad MJ; Costa FF; Saad ST FEBS Lett; 2003 Jan; 535(1-3):17-22. PubMed ID: 12560071 [TBL] [Abstract][Full Text] [Related]
37. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes. Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701 [TBL] [Abstract][Full Text] [Related]
38. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Chu S; Li L; Singh H; Bhatia R Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918 [TBL] [Abstract][Full Text] [Related]
39. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells. Zhang JH; He YL; Zhu R; Du W; Xiao JH Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894 [TBL] [Abstract][Full Text] [Related]
40. Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter. Nyga R; Pecquet C; Harir N; Gu H; Dhennin-Duthille I; Régnier A; Gouilleux-Gruart V; Lassoued K; Gouilleux F Biochem J; 2005 Aug; 390(Pt 1):359-66. PubMed ID: 15833084 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]